1. Home
  2. CHSCL vs REVBW Comparison

CHSCL vs REVBW Comparison

Compare CHSCL & REVBW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHSCL
  • REVBW
  • Stock Information
  • Founded
  • CHSCL N/A
  • REVBW N/A
  • Country
  • CHSCL United States
  • REVBW United States
  • Employees
  • CHSCL N/A
  • REVBW 9
  • Industry
  • CHSCL Farming/Seeds/Milling
  • REVBW Biotechnology: Pharmaceutical Preparations
  • Sector
  • CHSCL Industrials
  • REVBW Health Care
  • Exchange
  • CHSCL Nasdaq
  • REVBW Nasdaq
  • Market Cap
  • CHSCL N/A
  • REVBW N/A
  • IPO Year
  • CHSCL N/A
  • REVBW 2020
  • Fundamental
  • Price
  • CHSCL $25.53
  • REVBW $0.01
  • Analyst Decision
  • CHSCL
  • REVBW
  • Analyst Count
  • CHSCL 0
  • REVBW 0
  • Target Price
  • CHSCL N/A
  • REVBW N/A
  • AVG Volume (30 Days)
  • CHSCL N/A
  • REVBW N/A
  • Earning Date
  • CHSCL N/A
  • REVBW N/A
  • Dividend Yield
  • CHSCL N/A
  • REVBW N/A
  • EPS Growth
  • CHSCL N/A
  • REVBW N/A
  • EPS
  • CHSCL N/A
  • REVBW N/A
  • Revenue
  • CHSCL N/A
  • REVBW N/A
  • Revenue This Year
  • CHSCL N/A
  • REVBW N/A
  • Revenue Next Year
  • CHSCL N/A
  • REVBW N/A
  • P/E Ratio
  • CHSCL N/A
  • REVBW N/A
  • Revenue Growth
  • CHSCL N/A
  • REVBW N/A
  • 52 Week Low
  • CHSCL N/A
  • REVBW N/A
  • 52 Week High
  • CHSCL N/A
  • REVBW N/A
  • Technical
  • Relative Strength Index (RSI)
  • CHSCL 32.53
  • REVBW N/A
  • Support Level
  • CHSCL $25.77
  • REVBW N/A
  • Resistance Level
  • CHSCL $26.10
  • REVBW N/A
  • Average True Range (ATR)
  • CHSCL 0.17
  • REVBW 0.00
  • MACD
  • CHSCL -0.03
  • REVBW 0.00
  • Stochastic Oscillator
  • CHSCL 0.00
  • REVBW 0.00

About CHSCL CHS Inc Class B Cumulative Redeemable Preferred Stock Series 4

CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).

About REVBW Revelation Biosciences Inc. Warrant

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).

Share on Social Networks: